We all know that emphasis put on preventing the spread of corona virus 2 (SARS-CoV-2) of COVID-19 has not placed enough emphasis on stopping the spread of Covid-19 through identifying those carrying the virus with Point-of-Care testing and detecting antibody levels in those who have both had the virus and the vaccine.
MyBio have been providing anti-SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibody tests using immunochromatographic methods for well over 2 years to help provide information, particularly to research institutions of the approximate course of COVID-19 infection.
People are squeamish as we know and many find blood sampling off putting and often painful. At MyBio we are always interested in the different ways this sampling hesitation may be overcome.
In a recent study, a patch sensor integrating porous micro-needles (some may be familiar with such from the beauticians!) and an immunochromatographic assay (PMNIA) has been developed developed for the rapid detection of anti-SARS-CoV-2 IgM/IgG in dermal interstitial fluid (ISF).
ISF is a very a rich source of antibodies and these biodegradable porous microneedles extract the ISF vertically to the immunoassay biosensor. Then antibodies can be detected on site within 3 minutes. Read more here:
Reference: Bao L, Park J, Qin B, Kim B. Anti-SARS-CoV-2 IgM/IgG antibodies detection using a patch sensor containing porous microneedles and a paper-based immunoassay. Sci Rep. 2022;12(1):10693. doi: 10.1038/s41598-022-14725-6